We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An FDA employee who has publicly criticized the agency for not doing more to protect the public against the cardiovascular health risks associated with Vioxx is calling for patients to take naproxen instead of Cox-2 drugs and is urging the agency to reject Merck’s Vioxx successor Arcoxia, in an editorial recently published in the Journal of the American Medical Association (JAMA).
The “Dietary Supplement and Nonprescription Drug Consumer Protection Act” will cost the federal government $3 million in 2007 and $50 million from 2007 to 2011 if it becomes law, the Congressional Budget Office (CBO) estimated Sept. 12.
Congress members and staff have accepted at least $600,000 in travel since 2000, funded by trade groups such as AdvaMed and pharmaceutical companies, according to a Center for Public Integrity (CPI) report.
Drug and device companies and trade groups have funded at least $600,000 in trips for Congress members and staff, according to a report issued by the Center for Public Integrity (CPI).
Congress members and staff have accepted at least $600,000 in travel since 2000, funded by drug and device companies and trade groups, according to a report issued by the Center for Public Integrity (CPI).
A senator with a background in women’s health says Plan B should not be distributed OTC because the drug is a much stronger version of regular birth control, which requires a prescription.
The House yesterday passed a sweeping health information technology (HIT) bill that includes a provision designed to boost the use of electronic clinical trial data, but the measure came under swift attack by Democrats who charged that it would not improve technology adoption but would endanger the privacy of patient medical records.
The Department of Justice’s (DOJ) Antitrust Division has launched a criminal investigation into a proposed patent settlement between Bristol-Myers Squibb (BMS), sanofi-aventis and Apotex regarding the blood thinner Plavix, BMS announced July 27.
The biotech industry’s push for additional federal stem cell research funding failed July 19 as President Bush used the first veto of his presidency to send the legislation back to likely defeat in Congress.
While the House bucked the FDA by passing a medical device policy measure, the Senate seems less likely to agree to the provision regarding conflict-of-interest on device advisory boards.